Filing Details
- Accession Number:
- 0000950170-23-024600
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-26 19:10:49
- Reporting Period:
- 2023-05-24
- Accepted Time:
- 2023-05-26 19:10:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1582313 | Xenon Pharmaceuticals Inc. | XENE | Pharmaceutical Preparations (2834) | 980661854 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1619961 | Ian Mortimer | 200 - 3650 Gilmore Way Burnaby Z4 V5G 4W8 | President & Ceo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2023-05-24 | 42,592 | $9.44 | 48,592 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2023-05-24 | 7,310 | $41.84 | 41,282 | No | 4 | F | Direct | |
| Common Shares | Disposition | 2023-05-24 | 17,069 | $41.44 | 24,213 | No | 4 | S | Direct | |
| Common Shares | Acquisiton | 2023-05-24 | 20,576 | $9.85 | 44,789 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2023-05-24 | 3,902 | $41.84 | 40,887 | No | 4 | F | Direct | |
| Common Shares | Disposition | 2023-05-24 | 13,179 | $41.37 | 27,708 | No | 4 | S | Direct | |
| Common Shares | Acquisiton | 2023-05-24 | 6,172 | $9.85 | 33,880 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2023-05-24 | 1,171 | $41.84 | 32,709 | No | 4 | F | Direct | |
| Common Shares | Disposition | 2023-05-24 | 1,407 | $41.49 | 31,302 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Stock Option (Right to Buy) | Disposition | 2023-05-24 | 42,592 | $0.00 | 42,592 | $9.44 |
| Common Shares | Stock Option (Right to Buy) | Disposition | 2023-05-24 | 20,576 | $0.00 | 20,576 | $9.85 |
| Common Shares | Stock Option (Right to Buy) | Disposition | 2023-05-24 | 6,172 | $0.00 | 6,172 | $9.85 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2023-07-31 | No | 4 | M | Direct | |
| 0 | 2024-01-13 | No | 4 | M | Direct | |
| 0 | 2024-01-13 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Shares | 14,300 | Indirect | By Spouse. |
Footnotes
- The exercise price was converted from $9.76 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
- Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations.
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.29 to $41.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse StockSplit. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.26 to $41.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.48 to $41.52, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The shares subject to the option are fully vested and exercisable.
Billionaire Hedge Funds
